Gossamer Bio Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Gossamer Bio Inc 's ROA in the third quarter of 2026?
Gossamer Bio Inc recorded a cumulative net loss of $-123 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -111.49%.

However, within the Healthcare sector 762 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 4269, from total ROA ranking in the second quarter of 2026 at 4885.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	-68.63 %	-67.56 %	-53.38 %	-44.6 %	-41.56 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-123	-123	-180	-170	-156
Return On Assets (TTM)	-111.49 %	-84.69 %	-97.09 %	-76.5 %	-60.68 %
GOSS's Total Ranking	# 4269	# 4885	# 4158	# 4067	# 3529
Total Assets (TTM) in million	64	77	129	172	205
Seq. Total Assets Change	-16.3 %	-40.37 %	-25.17 %	-16 %	-13.47 %
Seq. Net Income Change	-	-	-	-	-

GOSS's 5 Years Annual ROA >> Back to GOSS Management Effectiveness >> Compare GOSS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 355
Sector	# 763
Overall	# 4287

Return On Assets Statistics
High	Average	Low
-7.8 %	-56.86 %	-111.49 %
(Mar 31 2019)		(Sep 30 2026)

Financial Statements
Gossamer Bio Inc 's Assets	$ 64 million	GOSS's Balance sheet
Gossamer Bio Inc 's Income	$ -48 million	Quarterly GOSS's Income Statement
GOSS's Income by Division		See GOSS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-44.6 %	0.56 %	14.99 %	-20.71 %	-36 %
Total Assets in million	172	311	309	269	339
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-170	-57	-180	-229	-234
Annual Return On Assets	-98.91 %	-18.18 %	-58.16 %	-85.31 %	-69.01 %

GOSS's 5 Years Annual ROA >> Back to GOSS Management Effectiveness >> Compare GOSS ROA to its Competitors

More Return On Assets Ratios
GOSS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GOSS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GOSS's Competitors
Subscribers only: Roa for Gossamer Bio Inc 's Suppliers
Subscribers only: Return On Assets for GOSS's Customers

You may also want to know
GOSS's Roi	GOSS's Inventory Turnover Ratio	GOSS's Growth Rates	GOSS's Dividend Comparisons
	GOSS's Profitability Ratios	GOSS's Asset Turnover Ratio	GOSS's Dividend Growth
GOSS's Roe	GOSS's Valuation Ratios	GOSS's Financial Strength Ratios	GOSS's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-11-11T13:44:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.